Table 1b.
Characteristics of relapse patients after second SCT: Late Relapse ≥ 180 days
| No 2nd SCT | Received 2nd SCT | P | |
|---|---|---|---|
| Number | 9 | 12 | |
| Gender (M/F) | 3/6 | 7/5 | NS |
| Age median/range (year) | 37 (9–44) | 36 (13–66) | NS |
| Disease status at 1st SCT | NS | ||
| AML CR1 | 1 | 3 | |
| CR2 | 1 | - | |
| >CR2/MDS | 1 | 6 | |
| CML AP | 1 | - | |
| BC | - | 1 | |
| ALL CR1 | 1 | - | |
| CR2/3 | 3 | 1 | |
| CLL | 1 | 1 | |
| Risk classification | NS | ||
| High risk | 2 (22%) | 7 (58%) | |
| Standard and Intermediate | 7 (78%) | 5 (42%) | |
| Karnofsky % median (range) | 90 (50–90) | 90 (50–90) | NS |
| Day of relapse post 1st SCT median (range) | 254 (181–3678) | 598 (220–5091) | NS |
| Treatment (excluding SCT) | |||
| DLI | 3 | 5 | NS |
| Chemo – remission intent | 5 | 5 | NS |
| Palliative or None | 3 | 5 | NS |
Abbreviations: SCT = stem cell transplantation; CML AP = CML in accelerated phase; CML BC = CML in blast phase; DLI = donor lymphocyte infusion; NS = not statistically significant